Nuraiym Sarsenkulova
Research Subjects
Nuraiym Sarsenkulova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kuandyk Zhugunissov
Research Institute for Biological Safety Problems, National Holding “QazBioPharm”, Gvardeiskiy, Kazakhstan
3 shared publications - Aisulu Valiyeva
Research Institute for Biological Safety Problems LLP, Guardeyskiy 080409, Kazakhstan
2 shared publications - Aslan Kerimbayev
Research Institute for Biological Safety Problems, National Holding “QazBioPharm”, Gvardeiskiy 080409, Kazakhstan
2 shared publications - Balzhan Myrzakhmetova
Research Institute for Biological Safety Problems, Gvardeiskiy 080409, Kazakhstan
2 shared publications - D. I. Muzarap
ТОО «Научно-исследовательский институт проблем биологической безопасности
2 shared publications - Marzhan Kenzhebaeva
ТОО «Научно-исследовательский институт проблем биологической безопасности
2 shared publications
Latest Publications
- Open Access
Dynamics of Orthopoxvirus Stability Under Simulated Luminal Conditions of the Gastrointestinal Tract for Assessing the Feasibility of Oral Immunization
Background/Objectives: Mpox (formerly monkeypox) is a re-emerging global health threat. While current vaccines are injectable, oral vaccination offers a painless alternative, though the harsh gastrointestinal (GI) environment challenges live viral vaccines. This study evaluated the stability of orthopoxviruses under simulated GI conditions to assess the physicochemical feasibility of oral mpox immunization. Methods: Attenuated and virulent strains of vaccinia, cowpox, and camelpox viruses were exposed to simulated gastric (pH 1.0–2.0 and 3.0–4.0 with pepsin) and intestinal (pH 7.0–7.5) conditions at 37 °C for 180 min. Viral titers were determined via cell culture assays. The physicochemical protective efficacy of enteric-coated capsules was evaluated using standard dissolution testing parameters. Results: All orthopoxviruses were rapidly inactivated under highly acidic fasting conditions (pH 1.0–2.0). However, they exhibited high stability at pH 3.0–4.0 and 7.0–7.5, retaining approximately 20–30% of their initial infectivity after 180 min. Enteric-coated capsules successfully maintained shell integrity in simulated gastric fluids for over 3 h and dissolved completely under intestinal conditions within ~130 min, aligning with small intestine transit times. Conclusions: Orthopoxviruses possess sufficient intestinal stability to support the physicochemical feasibility of oral immunization, provided they are protected from gastric acidity. Enteric-coated capsules represent a highly suitable delivery system for the intestinal release of live orthopoxvirus-based candidates, warranting further in vivo preclinical evaluation.
Open AccessDynamics of Orthopoxvirus Stability Under Simulated Luminal Conditions of the Gastrointestinal Tract for Assessing the Feasibility of Oral Immunization
Background/Objectives: Mpox (formerly monkeypox) is a re-emerging global health threat. While current vaccines are injectable, oral vaccination offers a painless alternative, though the harsh gastrointestinal (GI) environment challenges live viral vaccines. This study evaluated the stability of orthopoxviruses under simulated GI conditions to assess the physicochemical feasibility of oral mpox immunization. Methods: Attenuated and virulent strains of vaccinia, cowpox, and camelpox viruses were exposed to simulated gastric (pH 1.0–2.0 and 3.0–4.0 with pepsin) and intestinal (pH 7.0–7.5) conditions at 37 °C for 180 min. Viral titers were determined via cell culture assays. The physicochemical protective efficacy of enteric-coated capsules was evaluated using standard dissolution testing parameters. Results: All orthopoxviruses were rapidly inactivated under highly acidic fasting conditions (pH 1.0–2.0). However, they exhibited high stability at pH 3.0–4.0 and 7.0–7.5, retaining approximately 20–30% of their initial infectivity after 180 min. Enteric-coated capsules successfully maintained shell integrity in simulated gastric fluids for over 3 h and dissolved completely under intestinal conditions within ~130 min, aligning with small intestine transit times. Conclusions: Orthopoxviruses possess sufficient intestinal stability to support the physicochemical feasibility of oral immunization, provided they are protected from gastric acidity. Enteric-coated capsules represent a highly suitable delivery system for the intestinal release of live orthopoxvirus-based candidates, warranting further in vivo preclinical evaluation.
- Open Access
- 30 September 2025
- Published by West Kazakhstan Agrarian Technical University named after Zhangir Khan in Ġylym ža̋ne bìlìm
- Vol. 80 (3) , 184-196
APPROBATION TEST OF THE INACTIVATED EMULSIFIED MONOVALENT VACCINE AGAINST BLUETONGUEAND STUDY OF CROSS-IMMUNITY IN VACCINATED ANIMALS WITH OTHER VIRUS SEROTYPES
The article presents the results of the commission testing of the physicochemical and biological properties of the experimental series of the inactivated emulsified monovalent vaccine against bluetongue in animals at the National Reference Center for Veterinary of the Committee for Veterinary Control and Supervision of the Ministry of Agriculture of the Republic of Kazakhstan (CVCS MA RK). General virological and immunological research methods laid down in the regulatory and technical documentation (RTD) of the vaccine were used to conduct the study. The results of the commission studies showed that the vaccine is sterile with respect to foreign microflora, a harmless and immunogenic drug for sheep. On the 21st day after the administration of the vaccine, antibodies are detected in the animals in ELISA, the optical density of the serum of vaccinated animals ranges from 13% to 27%. According to the results of the commission testing, the vaccine meets the requirements laid down in the RTD of the drug. A registration certificate has been received for the drug. It is recommended to use the vaccine on a large scale in sheep and cattle farms, in private farmsteads for specific prevention of bluetongue. In addition, this article presents the results of determining the presence of cross-immunity in sheep infected with various serotypes of the bluetongue virus available at the Institute.
- 30 September 2025
- Published by West Kazakhstan Agrarian Technical University named after Zhangir Khan in Ġylym ža̋ne bìlìm
- Vol. 80 (3) , 184-196
Open AccessAPPROBATION TEST OF THE INACTIVATED EMULSIFIED MONOVALENT VACCINE AGAINST BLUETONGUEAND STUDY OF CROSS-IMMUNITY IN VACCINATED ANIMALS WITH OTHER VIRUS SEROTYPES
The article presents the results of the commission testing of the physicochemical and biological properties of the experimental series of the inactivated emulsified monovalent vaccine against bluetongue in animals at the National Reference Center for Veterinary of the Committee for Veterinary Control and Supervision of the Ministry of Agriculture of the Republic of Kazakhstan (CVCS MA RK). General virological and immunological research methods laid down in the regulatory and technical documentation (RTD) of the vaccine were used to conduct the study. The results of the commission studies showed that the vaccine is sterile with respect to foreign microflora, a harmless and immunogenic drug for sheep. On the 21st day after the administration of the vaccine, antibodies are detected in the animals in ELISA, the optical density of the serum of vaccinated animals ranges from 13% to 27%. According to the results of the commission testing, the vaccine meets the requirements laid down in the RTD of the drug. A registration certificate has been received for the drug. It is recommended to use the vaccine on a large scale in sheep and cattle farms, in private farmsteads for specific prevention of bluetongue. In addition, this article presents the results of determining the presence of cross-immunity in sheep infected with various serotypes of the bluetongue virus available at the Institute.
- Open Access
Field Trials of Live and Inactivated Camelpox Vaccines in Kazakhstan
An outbreak of camelpox occurred in the Mangistau region of Kazakhstan in 2019. To control the outbreak of camelpox and to prevent its further spread to other regions, camels were vaccinated using live and inactivated camelpox vaccines produced in Kazakhstan. To evaluate the efficacy of these camelpox vaccines in the field, vaccine trials used 172 camels on camel farms in the Beineu district. Of these, 132 camels were vaccinated using a live attenuated camelpox vaccine and 40 camels were vaccinated using an inactivated vaccine to observe immunogenicity and safety. The live vaccine was inoculated into camels by scarification at a dose of 5 × 104 EID50, and the inactivated vaccine was injected intramuscularly at 5 mL twice, with an interval of 35 days. During the safety evaluation, camels administered either vaccine displayed no clinical signs of illness or any adverse effects. Post-vaccination seroconversion demonstrated that the live attenuated vaccine started to elicit antibody responses in some animals as early as day seven, while, by day 28, 99% of vaccinated camels responded. For camels immunized with the inactivated vaccine, seroconversion began on day 21 at low titers ranging from 1:2 to 1:4. Ninety days post vaccination, 77% of the camels demonstrated an immune response that was up to a titer of 1:16. The antibody response waned six months post vaccination in camels vaccinated with two types of vaccine. Nonetheless, both vaccines were 100% effective at preventing clinical disease in vaccinated camels during the camelpox outbreak. All unvaccinated camels became ill, with manifestations of clinical signs characteristic of camelpox. Following these successful field trials in Kazakhstan, a vaccination program for camels, to control camelpox using the domestically produced live attenuated camelpox vaccine, has started.
Open AccessField Trials of Live and Inactivated Camelpox Vaccines in Kazakhstan
An outbreak of camelpox occurred in the Mangistau region of Kazakhstan in 2019. To control the outbreak of camelpox and to prevent its further spread to other regions, camels were vaccinated using live and inactivated camelpox vaccines produced in Kazakhstan. To evaluate the efficacy of these camelpox vaccines in the field, vaccine trials used 172 camels on camel farms in the Beineu district. Of these, 132 camels were vaccinated using a live attenuated camelpox vaccine and 40 camels were vaccinated using an inactivated vaccine to observe immunogenicity and safety. The live vaccine was inoculated into camels by scarification at a dose of 5 × 104 EID50, and the inactivated vaccine was injected intramuscularly at 5 mL twice, with an interval of 35 days. During the safety evaluation, camels administered either vaccine displayed no clinical signs of illness or any adverse effects. Post-vaccination seroconversion demonstrated that the live attenuated vaccine started to elicit antibody responses in some animals as early as day seven, while, by day 28, 99% of vaccinated camels responded. For camels immunized with the inactivated vaccine, seroconversion began on day 21 at low titers ranging from 1:2 to 1:4. Ninety days post vaccination, 77% of the camels demonstrated an immune response that was up to a titer of 1:16. The antibody response waned six months post vaccination in camels vaccinated with two types of vaccine. Nonetheless, both vaccines were 100% effective at preventing clinical disease in vaccinated camels during the camelpox outbreak. All unvaccinated camels became ill, with manifestations of clinical signs characteristic of camelpox. Following these successful field trials in Kazakhstan, a vaccination program for camels, to control camelpox using the domestically produced live attenuated camelpox vaccine, has started.